Abstract
The 3,4-dihydro-2(1H)-quinolinone moiety is present in a number of pharmacologically active compounds. These include FDA approved drugs such as cilostazol, carteolol and aripiprazole as well as numerous experimental compounds. Compounds containing the 3,4-dihydro-2(1H)-quinolinone moiety also exhibit a variety of activities in both the peripheral and central tissues, which includes phosphodiesterase inhibition, blocking of β-adrenergic receptors, antagonism of vasopressin receptors and interaction with serotonin and dopamine receptors. Based on its versatility in drug design and action, this paper reviews the pharmacological actions of compounds containing the 3,4-dihydro-2(1H)- quinolinone scaffold with emphasis being placed on the most important and significant members of each activity class.
Keywords: Aripiprazole, carteolol, cilostazol, 3, 4-dihydro-2(1H)-quinolinone, pharmacology, drug design.
Graphical Abstract
Mini-Reviews in Medicinal Chemistry
Title:A Review of the Pharmacological Properties of 3,4-dihydro-2(1H)- quinolinones
Volume: 18 Issue: 10
Author(s): Letitia Meiring, Jacobus P. Petzer and Anel Petzer*
Affiliation:
- Pharmaceutical Chemistry, School of Pharmacy and Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom 2520,south africa
Keywords: Aripiprazole, carteolol, cilostazol, 3, 4-dihydro-2(1H)-quinolinone, pharmacology, drug design.
Abstract: The 3,4-dihydro-2(1H)-quinolinone moiety is present in a number of pharmacologically active compounds. These include FDA approved drugs such as cilostazol, carteolol and aripiprazole as well as numerous experimental compounds. Compounds containing the 3,4-dihydro-2(1H)-quinolinone moiety also exhibit a variety of activities in both the peripheral and central tissues, which includes phosphodiesterase inhibition, blocking of β-adrenergic receptors, antagonism of vasopressin receptors and interaction with serotonin and dopamine receptors. Based on its versatility in drug design and action, this paper reviews the pharmacological actions of compounds containing the 3,4-dihydro-2(1H)- quinolinone scaffold with emphasis being placed on the most important and significant members of each activity class.
Export Options
About this article
Cite this article as:
Meiring Letitia , Petzer P. Jacobus and Petzer Anel*, A Review of the Pharmacological Properties of 3,4-dihydro-2(1H)- quinolinones, Mini-Reviews in Medicinal Chemistry 2018; 18 (10) . https://dx.doi.org/10.2174/1389557517666170927141323
DOI https://dx.doi.org/10.2174/1389557517666170927141323 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review
Current Neuropharmacology Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets Chromium-Picolinate Therapy in Diabetes Care: Individual Outcomes Require New Guidelines and Navigation by Predictive Diagnostics
Infectious Disorders - Drug Targets Mitochondrial Uncoupler Proteins
Current Enzyme Inhibition FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Beta-blockers in Children with Duchenne Cardiomyopathy
Reviews on Recent Clinical Trials Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry